Free Trial
NASDAQ:PRQR

ProQR Therapeutics Q2 2025 Earnings Report

ProQR Therapeutics logo
$2.16 0.00 (0.00%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$2.18 +0.02 (+0.93%)
As of 09/23/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProQR Therapeutics EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.08
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

ProQR Therapeutics Revenue Results

Actual Revenue
$4.33 million
Expected Revenue
$5.01 million
Beat/Miss
Missed by -$677.00 thousand
YoY Revenue Growth
N/A

ProQR Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

ProQR Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Friday, November 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

ProQR Therapeutics Earnings Headlines

China’s message to Trump
Did China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of military power. Fighter jets, tanks, AI-guided drones — all paraded under the red flag, in front of Vladimir Putin, Kim Jong Un, and more than two dozen world leaders.tc pixel
See More ProQR Therapeutics Headlines

About ProQR Therapeutics

ProQR Therapeutics (NASDAQ:PRQR) is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives. Its dual-platform approach—combining site-directed RNA editing with direct RNA therapies—underpins efforts to address a range of monogenic disorders affecting the eye, skin and other organ systems. By focusing on mRNA modulation rather than permanent DNA edits, ProQR seeks to deliver treatments that may offer reversibility and a favorable safety profile.

ProQR has advanced multiple programs into early- and mid-stage clinical trials in North America and Europe, collaborating with leading academic institutions and industry partners. Multidisciplinary teams in molecular biology, translational research, and clinical development drive the company’s efforts to demonstrate proof of concept and navigate regulatory pathways. Ongoing studies aim to establish dosing, safety and efficacy in patient populations with high unmet medical needs.

Led by CEO Daniel de Boer and supported by a management team with extensive expertise in biotechnology and ophthalmology, ProQR continues to refine its platforms and expand its pipeline. The company actively pursues strategic partnerships and funding opportunities to accelerate its mission of transforming lives through innovative RNA medicines for rare genetic disorders.

View ProQR Therapeutics Profile

More Earnings Resources from MarketBeat